Clinical Trial Update: Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial exploring nivolumab added to gemcitabine/S-1 in metastatic pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• S-1 (tegafur/gimeracil/oteracil)
• nivolumab (nivolumab)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Stage IV Pancreatic Cancer | Phase 2 | Status: UNKNOWN